When will the EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE patents expire, and when will EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE go generic?

Sponsor	Phase
ViiV Healthcare	Phase 3
Janssen, LP	Phase 3
Quest Clinical Research	Phase 4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	214095-001	Jan 30, 2026		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 17, 2026

Odefsey, the fixed-dose combination of emtricitabine, rilpivirine, and tenofovir alafenamide, remains a significant branded HIV treatment for virologically suppressed patients and selected treatment-naive adults. Gilead Sciences markets the product in the United States and globally. Its commercial position is supported by the safety and renal-bone profile of tenofovir alafenamide, but constrained by competition from Biktarvy, Dovato, Triumeq, long-acting Cabenuva, and generic or authorized-generic pressure affecting older antiretroviral regimens.

Odefsey generated approximately $1 billion in annual global product sales in recent years. The product is mature rather than high-growth, with future performance dependent on patient switching, treatment guidelines, contracting, geographic access, and the timing of generic entry.

What is Odefsey and how does it work?

Odefsey is a once-daily tablet containing:

Active ingredient	Dose	Drug class	Function
Emtricitabine	200 mg	Nucleoside reverse transcriptase inhibitor	Inhibits HIV reverse transcriptase
Rilpivirine	25 mg	Non-nucleoside reverse transcriptase inhibitor	Inhibits HIV reverse transcriptase
Tenofovir alafenamide	25 mg	Nucleotide reverse transcriptase inhibitor	Delivers tenofovir intracellularly

The U.S. Food and Drug Administration approved Odefsey on March 1, 2016, for treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kilograms. The label covers patients without prior antiretroviral treatment with HIV-1 RNA of 100,000 copies per milliliter or less, and patients who are virologically suppressed on a stable regimen without a history of treatment failure or known resistance to the product’s components (FDA, 2024a).

Odefsey must be taken with a meal. Rilpivirine has important drug-interaction and virologic-resistance limitations. The label excludes patients with certain resistance substitutions and prohibits use with proton-pump inhibitors.

What is the FDA regulatory status of Odefsey?

Odefsey is an FDA-approved complete antiretroviral regimen. It is not a biologic and therefore does not face biosimilar competition under the Public Health Service Act. Future competition will arise primarily through abbreviated new drug applications, fixed-dose combination products, component-level generics, and branded alternatives.

Key FDA milestones

Event	Date
FDA approval	March 1, 2016
Active ingredients	Emtricitabine, rilpivirine, tenofovir alafenamide
Dosage form	Oral, once-daily tablet
Approved patient weight	At least 35 kg
Primary disease area	HIV-1 infection
Regulatory pathway	New drug application
Biosimilar pathway	Not applicable

The product’s commercial utility is narrower than that of Biktarvy because rilpivirine is less forgiving of high baseline viral load, food restrictions, drug interactions, and resistance. Odefsey nevertheless retains value for stable, suppressed patients seeking a smaller tenofovir exposure profile than older TDF-based regimens.

How have Odefsey sales developed?

Gilead does not always present Odefsey revenue in the same level of detail across every filing, and reported amounts may vary by geographic presentation and foreign-exchange treatment. Public annual reports indicate that Odefsey has maintained approximately $1 billion in annual global sales in the early 2020s.

Fiscal year	Approximate global Odefsey sales	Market interpretation
2019	About $1.0 billion	Mature product with strong switch activity
2020	About $1.0 billion	Resilient demand despite pandemic disruption
2021	About $1.0 billion	Stable branded HIV revenue
2022	About $1.0 billion	Offset by competition from newer regimens
2023	About $1.0 billion	Mature, cash-generative franchise product
2024	Approximately $1.0 billion range	Continued erosion risk, partly offset by treatment durability

Source basis: Gilead Sciences annual reports and Form 10-K filings, which report HIV product sales and product-level revenue where disclosed (Gilead Sciences, 2020-2024).

Odefsey is materially smaller than Biktarvy. Biktarvy has become Gilead’s principal HIV growth product, with annual sales exceeding $10 billion. Odefsey’s role is closer to a durable maintenance product: it generates substantial cash flow but has limited ability to expand its addressable market against newer regimens.

How does Odefsey compare with Biktarvy, Dovato, and Cabenuva?

Product	Company	Regimen type	Main commercial advantage	Main limitation relative to Odefsey
Odefsey	Gilead	FTC/RPV/TAF, once daily	Compact tablet and TAF-based profile	Food requirement, rilpivirine restrictions, lower resistance forgiveness
Biktarvy	Gilead	BIC/FTC/TAF, once daily	Broad use, high potency, strong treatment guidelines	Higher cost and continued patent dependence
Dovato	ViiV Healthcare	DTG/3TC, once daily	Two-drug regimen and reduced NRTI exposure	Patient-selection and clinical considerations
Triumeq	ViiV Healthcare	DTG/ABC/3TC, once daily	Established efficacy and broad historical use	Abacavir cardiovascular and HLA-B*5701 considerations
Cabenuva	ViiV Healthcare	Long-acting CAB/RPV injections	Reduces daily pill burden	Injection administration, clinic logistics, cost
Complera	Gilead	FTC/RPV/TDF, once daily	Earlier rilpivirine fixed-dose option	TDF renal and bone limitations; largely displaced by Odefsey

Biktarvy is the principal internal substitute. Both products contain emtricitabine and tenofovir alafenamide, but Biktarvy uses bictegravir rather than rilpivirine. Gilead has a commercial incentive to manage switching within its portfolio rather than lose patients to ViiV or other regimens.

Cabenuva creates a different form of competitive pressure. It targets patients who prioritize freedom from daily oral therapy, although reimbursement, injection visits, cold-chain requirements, and implementation capacity limit universal adoption.

When does Odefsey lose exclusivity?

Odefsey’s exclusivity is not determined by a single date. It depends on:

New chemical entity and regulatory exclusivity.
FDA-listed patents covering the combination, components, formulations, and methods of use.
Pediatric exclusivity.
Patent-term adjustments or extensions.
Paragraph IV challenges and settlement agreements.
The ability of an ANDA applicant to design around listed claims.

The product’s five-year new chemical entity exclusivity period expired in 2021. That date did not by itself authorize generic entry because FDA-listed patents and other market barriers can continue after regulatory exclusivity expires.

The relevant patent estate is distributed across Gilead’s tenofovir alafenamide, rilpivirine, fixed-dose combination, formulation, and treatment-method portfolios. Publicly available FDA Orange Book records should be treated as the controlling source for current listed patents and expiration information, because listings can change through delistings, certifications, patent-term adjustments, and litigation outcomes (FDA, 2024b).

What patents protect Odefsey?

The commercial patent estate has historically included claims directed to:

Tenofovir alafenamide and its fumarate salt.
Pharmaceutical compositions containing tenofovir alafenamide.
Combinations of tenofovir alafenamide with emtricitabine and a third antiretroviral.
Rilpivirine-containing HIV treatment regimens.
Fixed-dose tablets and pharmaceutical formulations.
Methods of treating HIV infection with the combination.
Dosing and administration conditions involving food and virologic suppression.

The strongest remaining barriers are likely to be patents covering the active combination and TAF-based formulation rather than the older emtricitabine or rilpivirine molecules individually. Those claims can remain commercially relevant even when individual component patents have expired.

What is the Orange Book status of Odefsey?

Odefsey is listed in the FDA Orange Book under NDA 208351. The Orange Book identifies patents and regulatory exclusivities that an ANDA applicant must address. An applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed under Paragraph IV.

An ANDA approval may be delayed by:

A Paragraph IV lawsuit filed within 45 days.
A statutory 30-month stay.
Patent-term adjustments.
Court injunctions or preliminary relief.
A settlement that grants a future launch license.
Label carve-outs for method-of-use claims.

An Orange Book listing does not guarantee that a patent will survive litigation. Conversely, the absence of a publicly visible litigation headline does not establish that no ANDA has been filed.

Which companies are challenging Odefsey?

Generic competition is expected to come from large ANDA manufacturers with HIV portfolios, including Teva, Mylan/Viatris, Cipla, Lupin, Aurobindo, Dr. Reddy’s, and other international manufacturers. The actual competitive set depends on confidential FDA filings, Paragraph IV certifications, manufacturing approvals, and settlement terms.

No biosimilar challenge is relevant because Odefsey is a small-molecule tablet. The main legal risk is an ANDA applicant obtaining approval after invalidating or avoiding the remaining Orange Book claims.

What generic entry risks exist for Odefsey?

Generic entry could occur in several forms:

Entry scenario	Commercial effect
Authorized generic	Lower-price alternative controlled or licensed by the originator
Single generic Odefsey equivalent	Rapid price discounting in public and commercial channels
Multiple generic entrants	Larger reimbursement erosion and contracting pressure
Component substitution	Patients moved to separate emtricitabine, rilpivirine, and TAF products
Therapeutic substitution	Switching to generic TDF-, dolutegravir-, or lamivudine-based regimens
Label carve-out	Partial competition if method-of-use claims remain protected

The largest risk is not necessarily immediate loss of all Odefsey prescriptions. HIV treatment is heavily influenced by formularies, physician familiarity, resistance history, adherence, and continuity of care. Stable patients can remain on the branded product even after generic approval if rebates and payer policies delay mandatory substitution.

How strong is the Odefsey patent estate?

Odefsey has a medium-strength commercial patent position.

The estate benefits from:

Multiple active ingredients and patent families.
The technical value of TAF-based delivery.
Fixed-dose combination claims.
Clinical switching and maintenance uses.
Gilead’s established HIV regulatory and litigation infrastructure.

The estate faces pressure from:

Expiration of older component patents.
Potential patent-term differences across jurisdictions.
The ability to separate the components or design around combination claims.
Clinical substitution by Biktarvy and other integrase-inhibitor regimens.
The maturity of the product and limited new-label expansion.

The patent estate is more valuable as a portfolio-management tool than as a long-term growth engine. Gilead can use it to delay or shape generic entry, but it cannot prevent therapeutic migration indefinitely.

What patent litigation and settlement issues affect Odefsey?

The key litigation question is whether an ANDA applicant has filed a Paragraph IV certification against a current Orange Book patent. A litigation filing can delay approval for up to 30 months unless the court resolves the case earlier. Settlements may provide a licensed generic launch date before the final patent expiration.

For Odefsey, commercial exposure depends on the settlement structure:

A date-certain entry agreement could preserve revenue until a negotiated launch.
An authorized-generic arrangement could limit price erosion.
A covenants-not-to-sue agreement could permit narrow entry.
A litigation victory could preserve the brand until the patent expires.
A patent invalidity ruling could trigger rapid multi-generic entry.

Publicly disclosed Gilead filings should be used to identify material litigation, settlement payments, and launch dates. Product-level public disclosure is not always complete.

What is the geographic market outlook?

The United States is the most valuable market because of higher net pricing, commercial insurance, Medicare, Medicaid, and government purchasing programs. Europe has stronger price controls and centralized procurement, producing earlier revenue compression after generic or tender competition. Emerging markets are more volume-driven and often have earlier access to lower-cost antiretroviral alternatives.

Odefsey’s geographic performance depends on:

National HIV treatment guidelines.
TAF availability and registration.
Local tender awards.
Patent enforcement standards.
Voluntary licensing.
Manufacturing capacity.
Access programs and public-health procurement.

Gilead’s voluntary licensing and access strategies are more important for HIV medicines in low- and middle-income countries than for U.S. revenue protection. They can expand patient access while limiting the commercial value of exclusivity in those markets.

What manufacturing and intellectual-property barriers protect Odefsey?

The manufacturing barrier is moderate. Odefsey is an oral tablet and does not require biologic cell-line manufacturing, sterile injectable production, or complex delivery-device technology. Generic manufacturers must still establish:

Bioequivalence for the fixed-dose tablet.
Control of multiple active ingredients.
Stability and impurity specifications.
Consistent TAF salt and formulation performance.
Compliance with FDA current good manufacturing practices.
Acceptable dissolution and food-effect characteristics.

TAF manufacturing and formulation know-how can create practical barriers, but those barriers are less durable than biologic manufacturing barriers. Once an approved generic pathway is established, several manufacturers can compete.

What is the revenue exposure from Odefsey?

Odefsey represents a meaningful but declining component of Gilead’s HIV franchise. At approximately $1 billion in annual sales, a 30% net-price decline after generic entry could imply roughly $300 million of annual product-level revenue exposure before accounting for volume changes, geographic timing, and portfolio switching.

Scenario	Indicative revenue impact
Continued branded maintenance	Low-single-digit annual erosion
Biktarvy-led internal switching	Odefsey decline with partial Gilead retention
Single generic entrant	Moderate price and volume pressure
Multiple generic entrants	Severe net-price erosion
Early authorized generic	Controlled erosion but lower brand revenue
Broad therapeutic substitution	Greater loss to competing companies

Biktarvy reduces Gilead’s net exposure because some Odefsey patients may remain within the Gilead portfolio. That offset is commercially important, but Biktarvy’s own patent and pricing risks limit the value of relying on internal switching alone.

What is the likely market trajectory for Odefsey?

Odefsey is likely to follow a mature-product trajectory:

Stable or modestly declining sales while branded access remains favorable.
Continued switching to Biktarvy and two-drug regimens.
Selective retention among suppressed patients who tolerate rilpivirine and prefer a compact once-daily tablet.
Increasing payer pressure as cheaper alternatives become available.
Significant price erosion after broad generic entry.
Greater erosion outside the United States because of tendering and price controls.

The product remains strategically relevant because it is part of Gilead’s HIV franchise and offers a TAF-based alternative to older TDF regimens. Its long-term value depends less on new patient starts than on treatment continuity, formulary placement, and controlled migration within Gilead’s portfolio.

Key Takeaways

Odefsey is the fixed-dose combination of emtricitabine, rilpivirine, and tenofovir alafenamide.
FDA approval occurred in March 2016 under NDA 208351.
The product generates approximately $1 billion in annual global sales.
Biktarvy is the principal competitive and internal substitution product.
Regulatory exclusivity expired earlier than the full patent estate.
Generic entry risk centers on Orange Book patents, Paragraph IV certifications, litigation, and settlement dates.
Odefsey has no biosimilar risk because it is a small-molecule oral tablet.
The patent estate is commercially meaningful but less durable than a biologic or complex injectable product.
The greatest financial exposure is post-generic net-price erosion, partly offset by switching to other Gilead HIV products.
Long-term revenue is expected to decline as integrase-inhibitor regimens, two-drug therapies, long-acting injections, and generics gain share.

FAQs

Is Odefsey the same as Complera?

No. Both contain emtricitabine and rilpivirine, but Odefsey contains tenofovir alafenamide while Complera contains tenofovir disoproxil fumarate. Odefsey was developed to provide the TAF formulation’s lower circulating tenofovir exposure.

Can Odefsey be replaced by Biktarvy?

A physician may switch an eligible patient from Odefsey to Biktarvy after reviewing resistance history, renal function, hepatitis B status, drug interactions, and treatment response. The products are not automatically interchangeable.

Does Odefsey treat hepatitis B?

Odefsey contains emtricitabine and tenofovir alafenamide, which have activity against hepatitis B virus. However, discontinuation in a patient with hepatitis B can cause severe exacerbation. Clinical management must follow the product label.

What is the main clinical weakness of rilpivirine in Odefsey?

Rilpivirine has food requirements, acid-suppressing drug interactions, and a lower resistance barrier than integrase inhibitors. These factors restrict its use in some newly treated or treatment-experienced patients.

Will generic Odefsey immediately eliminate branded sales?

No. Generic approval can produce rapid price pressure, but the timing and scale of substitution depend on the number of entrants, payer mandates, authorized-generic arrangements, contracting, physician behavior, and patient stability.

References

Gilead Sciences, Inc. (2020-2024). Annual reports and Form 10-K filings. https://www.gilead.com/investors/financial-information/annual-reports
U.S. Food and Drug Administration. (2024a). Odefsey prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024c). Drugs@FDA: Odefsey, NDA 208351. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov. https://clinicalinfo.hiv.gov/en/guidelines

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	5
DailyMed Link:	EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE at DailyMed

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE Drug Patent Profile

Which patents cover Emtricitabine, Rilpivirine, And Tenofovir Alafenamide, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

Recent Clinical Trials for EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

US Patents and Regulatory Information for EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Market Dynamics and Financial Trajectory